PHARMACOLOGICALLY BASED PHASE-I TRIALS IN CANCER-CHEMOTHERAPY

被引：12

作者：

NEWELL, DR

机构：

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 1994年 / 8卷 / 02期

关键词：

D O I：

10.1016/S0889-8588(18)30172-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：257 / 275

页数：19

共 65 条

[21] CONCEPT OF MAXIMUM TOLERATED SYSTEMIC EXPOSURE AND ITS APPLICATION TO PHASE-I-II STUDIES OF ANTICANCER DRUGS [J].

EVANS, WE ;

RODMAN, JH ;

RELLING, MV ;

CROM, WR ;

RIVERA, GK ;

PRATT, CB ;

CRIST, WM .

MEDICAL AND PEDIATRIC ONCOLOGY, 1991, 19 (03) :153-159

[22] PRECLINICAL, PHASE-I AND PHARMACOKINETIC STUDIES WITH THE DIMETHYL PHENYLTRIAZENE-CB10-277 [J].

FOSTER, BJ ;

NEWELL, DR ;

CARMICHAEL, J ;

HARRIS, AL ;

GUMBRELL, LA ;

JONES, M ;

GOODARD, PM ;

CALVERT, AH .

BRITISH JOURNAL OF CANCER, 1993, 67 (02) :362-368

[23] PHASE-I TRIAL WITH PHARMACOKINETICS OF CB10-277 GIVEN BY 24 HOURS CONTINUOUS INFUSION [J].

FOSTER, BJ ;

NEWELL, DR ;

GUMBRELL, LA ;

JENNS, KE ;

CALVERT, AH .

BRITISH JOURNAL OF CANCER, 1993, 67 (02) :369-373

[24]

GHAZALASWAD S, 1993, BR J CANCER S20, V67, P37

[25] PHARMACOLOGY AND CLINICAL TOXICITY OF 4'-IODO-4'-DEOXYDOXORUBICIN - AN EXAMPLE OF SUCCESSFUL APPLICATION OF PHARMACOKINETICS TO DOSE ESCALATION IN PHASE-I TRIALS [J].

GIANNI, L ;

VIGANO, L ;

SURBONE, A ;

BALLINARI, D ;

CASALI, P ;

TARELLA, C ;

COLLINS, JM ;

BONADONNA, G .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (06) :469-477

[26] DOSE-ESCALATION STUDY OF CARBOPLATIN (DAY-1) AND CISPLATIN (DAY-3) - TOLERANCE AND RELATION TO LEUKOCYTE AND BUCCAL CELL PLATINUM DNA ADDUCTS [J].

GILL, I ;

MUGGIA, FM ;

TERHEGGEN, PMAB ;

MICHAEL, C ;

PARKER, RJ ;

KORTES, V ;

GRUNBERG, S ;

CHRISTIAN, MC ;

REED, E ;

DENENGELSE, L .

ANNALS OF ONCOLOGY, 1991, 2 (02) :115-121

[27] PHASE-I STUDY OF AN ANTI-BREAST CANCER IMMUNOTOXIN BY CONTINUOUS INFUSION - REPORT OF A TARGETED TOXIC EFFECT NOT PREDICTED BY ANIMAL STUDIES [J].

GOULD, BJ ;

BOROWITZ, MJ ;

GROVES, ES ;

CARTER, PW ;

ANTHONY, D ;

WEINER, LM ;

FRANKEL, AE .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (10) :775-781

[28]

GRAHAM MA, 1992, CANCER RES, V52, P603

[29] THE IMPACT OF PHARMACOKINETICALLY GUIDED DOSE ESCALATION STRATEGIES IN PHASE-I CLINICAL-TRIALS - CRITICAL-EVALUATION AND RECOMMENDATIONS FOR FUTURE STUDIES [J].

GRAHAM, MA ;

WORKMAN, P .

ANNALS OF ONCOLOGY, 1992, 3 (05) :339-347

[30]

GRIESHABER CK, 1986, CANCER TREAT REP, V70, P65

← 1 2 3 4 5 6 7 →